卵巢癌血清标志物的临床应用

doi:10.3969/j.issn.1673-8640.2015.08.022

摘要/Abstract

摘要：

卵巢癌死亡率在女性所有肿瘤死亡率中居第5位,妇科肿瘤中居首位。与乳腺癌不同,卵巢癌早期缺乏明显症状和有效筛查,生存率低。目前,美国食品药品管理局(FDA)只批准了少数卵巢癌的肿瘤标志物检测项目。卵巢癌的肿瘤标志物在疾病诊断、疗效监测和预后判断中被广泛应用。文章综述了现有卵巢癌的肿瘤标志物及其临床应用。

关键词: 糖类抗原125, 人附睾蛋白4, 卵巢癌

Abstract:

Ovarian cancer is the fifth cause of cancer death in women, as well as the cause of deaths in gynecological cancers. Unlike breast cancer, many women die of ovarian cancer because there is no obvious symptom and no screening test in early stages. Nowadays, only a limited number of tumor markers for ovarian cancer has been cleared by U.S. Food and Drug Administration (FDA). In general, tumor marker applications range from diagnosis and curative effect monitoring to predicting prognosis. The article will review the currently available serum markers for ovarian cancer and their clinical application.

Key words: Carbohydrate antigen 125, Human epididymis protein 4, Ovarian cancer

中图分类号:

R446.62

宋斌斌, 潘柏申. 卵巢癌血清标志物的临床应用[J]. 检验医学, 2015, 30(8): 866-870.

SONG Binbin, PAN Baishen. Clinical application of serum biomarkers for ovarian cancer[J]. Laboratory Medicine, 2015, 30(8): 866-870.

图/表 1

参考文献 25

[1]	American College of Obstetricians and Gynecologists Committee on Gynecologic Practice.Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer[J]. Obstet Gynecol,2011,117(3):742-746.
[2]	MUNKARAH A,CHATTERJEE M,TAINSKY MA.Update on ovarian cancer screening[J]. Curr Opin Obstet Gynecol,2007,19(1):22-26.
[3]	BUYS SS,PARTRIDGE E,BLACK A,et al.Effect of screening on ovarian cancer mortality: The prostate,lung,colorectal and ovarian (PLCO) cancer screening pandomized controlled trial[J]. JAMA,2011,305(22):2295-2303.
[4]	BALDWIN LM,TRIVERS KF,MATTHEWS B,et al.Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations[J] Ann Intern Med,2012,156(3):182-194.
[5]	BAST RC JR,XU FJ,YU YH,et al.CA 125: the past and the future[J]. Int J Biol Markers,1998,13(4):179-187.
[6]	PARTRIDGE EE,BARNES MN.Epithelial ovarian cancer: prevention,diagnosis,and treatment[J]. CA Cancer J Clin,1999,49(5):297-320.
[7]	中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J]. 中华检验医学杂志,2012,35(2):103-116.
[8]	KIRCHHOFF C,HABBEN I,IVELL R,et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J]. Biol Reprod,1991,45(2):350-357.
[9]	MOORE RG,BROWN AK,MILLER MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol,2008,108(2):402-408.
[10]	HUHTINEN K,SUVITIE P,HIISSA J,et al.Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts[J]. Br J Cancer,2009,100(8):1315-1319.
[11]	TUXEN MK,SÖLÉTORMOS G,DOMBERNOWSKY P.Tumor markers in the management of patients with ovarian cancer[J]. Cancer Treat Rev,1995,21(3):215-245.
[12]	VARTIAINEN J,LEHTOVIRTA P,FINNE P,et al.Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer[J]. Int J Cancer,2001,95(5):313-316.
[13]	DIAMANDIS EP,YOUSEF GM.Human tissue kallikreins: a family of new cancer biomarkers[J]. Clin Chem,2002,48(8):1198-1205.
[14]	DIAMANDIS EP,YOUSEF GM,SOOSAIPILLAI AR,et al.Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma[J]. Clin Biochem,2000,33(7):579-583.
[15]	DONG Y,KAUSHAL A,BUI L,et al.Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas[J]. Clin Cancer Res,2001,7(8):2363-2371.
[16]	LUO LY,KATSAROS D,SCORILAS A,et al.The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis[J]. Cancer Res,2003,63(4):807-811.
[17]	KIM JH,SKATES SJ,UEDE T,et al.Osteopontin as a potential diagnostic biomarker for ovarian cancer[J]. JAMA,2002,287(13):1671-1679.
[18]	SCHORGE JO,DRAKE RD,LEE H,et al.Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer[J]. Clin Cancer Res,2004,10(10):3474-3478.
[19]	JACOBS I,ORAM D,FAIRBANKS J,et al.A risk of malignancy index incorporating CA 125,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer[J].Br J Obstet Gynaecol,1990,97(10):922-929.
[20]	MOORE RG,JABRE-RAUGHLEY M,BROWN AK,et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am J Obstet Gynecol,2010,203(3):228.e1-e6.
[21]	VAN GORP T,VELDMAN J,VAN CALSTER B,et al.Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses[J]. Eur J Cancer,2012,48(11):1649-1656.
[22]	MENON U,SKATES SJ,LEWIS S,et al.Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer[J]. J Clin Oncol,2005,23(31):7919-7926.
[23]	LU KH,SKATES S,HERNANDEZ MA,et al.A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value[J]. Cancer,2013,119(19):3454-3461.
[24]	MOORE RG,MILLER MC,DISILVESTRO P,et al.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol,2011,118(2 Pt 1):280-288.
[25]	UELAND FR,DESIMONE CP,SEAMON LG,et al.Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors[J]. Obstet Gynecol,2011,117(6):1289-1297.

临床应用	单一血清标志物		多因素联合模型
临床应用	CA125	HE4	OVA1	RMI	ROMA	ROCA
一般人群筛查	否	否	否	否	否	是
盆腔肿块良恶性鉴别	是	是	是	是	是	否
治疗监测	是	是	否	否	否	否
复发预测	是	是	否	否	否	否

临床应用	单一血清标志物		多因素联合模型
临床应用	CA125	HE4	OVA1	RMI	ROMA	ROCA
一般人群筛查	否	否	否	否	否	是
盆腔肿块良恶性鉴别	是	是	是	是	是	否
治疗监测	是	是	否	否	否	否
复发预测	是	是	否	否	否	否